This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Penumbra (PEN) and BioCryst (BCRX)

Tipranks - Tipranks - Fri May 8, 6:52AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Revolution Medicines (RVMD), Penumbra (PEN) and BioCryst (BCRX).

Claim 55% Off TipRanks

Revolution Medicines (RVMD)

RBC Capital analyst Leonid Timashev maintained a Buy rating on Revolution Medicines yesterday and set a price target of $165.00. The company’s shares closed last Wednesday at $151.07.

According to TipRanks.com, Timashev is a 5-star analyst with an average return of 19.8% and a 57.0% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Perspective Therapeutics, and Edgewise Therapeutics. ;'>

Currently, the analyst consensus on Revolution Medicines is a Strong Buy with an average price target of $179.18, a 22.1% upside from current levels. In a report issued on April 22, Guggenheim also maintained a Buy rating on the stock with a $175.00 price target.

See the top stocks recommended by analysts >>

Penumbra (PEN)

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Penumbra, with a price target of $374.00. The company’s shares closed last Wednesday at $324.19.

According to TipRanks.com, Chadha is a 1-star analyst with an average return of -1.1% and a 42.5% success rate. Chadha covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Edwards Lifesciences. ;'>

Penumbra has an analyst consensus of Hold, with a price target consensus of $356.33, a 10.0% upside from current levels. In a report released today, Citi also maintained a Hold rating on the stock with a $350.00 price target.

BioCryst (BCRX)

Wedbush analyst Laura Chico maintained a Buy rating on BioCryst today and set a price target of $21.00. The company’s shares closed last Wednesday at $8.83, close to its 52-week high of $9.50.

According to TipRanks.com, Chico is a 5-star analyst with an average return of 13.4% and a 52.3% success rate. Chico covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ultragenyx Pharmaceutical, and Sionna Therapeutics, Inc. ;'>

BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $22.57, representing a 161.5% upside. In a report released yesterday, TipRanks – OpenAI also upgraded the stock to Buy with a $10.00 price target.

Read More on RVMD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).